ricevuto da Francesco Troccoli
Herald Tribune: pag. 13 - 19, 20 giugno 2004
GlaxoSmithKline, accusata di avere nascosto parte dei dati sperimentali dell'antidepressivo Paxil, ha annunciato di avere l'intenzione di pubblicare sul Web i risultati di tutti i clinical trials sul farmaco. La società ha già pubblicato sul suo sito gli studi che l'accusa ritiene siano stati occultati precedentemente
"First World", servizio internazionale di notizie nel farmaceutico, 06/18/2004
GlaxoSmithKline to set up public clinical trial database
by Candace Hoffmann
GlaxoSmithKline said that it is setting up a public database, which is the first of its kind by a drugmaker, of Glaxo-sponsored clinical studies of its marketed drugs, news sources report. The on-line database will be called the GSK Clinical Trial Register.
Glaxo spokesman Chris Hunter-Ward said that the database has been under consideration for several months, as reported in Bloomberg. "We think it's an important step in restoring public faith in medical research," Hunter-Ward is quoted as saying in an interview. The database will be available to physicians and the public in the third quarter and contain clinical trial data going back four years.
Glaxo's announcement came shortly after the American Medical Association said earlier this week that it would recommend the establishment of rules requiring all drugmakers to disclose clinical trials in a US public registry, as reported in Bloomberg. The drugmaker also recently posted the results of its trials of Paxil's use in children on its Web site in response to a lawsuit filed by New York's attorney general, alleging that it suppressed negative data on the drug.
"Glaxo is trying to improve transparency given the situation it finds itself in with [New York Attorney General Eliot Spitzer], Code Securities' analyst Mike Ward is quoted as saying. But Glaxo CEO Jean-Pierre Garnier said that the establishment of the database is not in response to Spitzer's lawsuit, instead it is related to the AMA's recent motion. "I think this is the right thing to do. We think more transparency is better," Garnier is quoted as saying, as reported in Yahoo Finance, "We don't want to be accused of anything about the way we deal with trials. I think it too important a subject."
Attorney General Spitzer is quoted as saying, in response to Glaxo's decision to create the database, "This is another positive step toward providing important and necessary information to doctors and the public," as reported in Yahoo Finance.
